NeoImmuneTech's Hyleukin-7 to be tested with Keytruda in solid tumors

11 December 2019
neoimmunetech_large

Privately-held US biotech NeoImmuneTech has joined the club of companies testing their therapeutic alongside Merck & Co’s (NYSE: MRK) blockbuster immuno-oncology drug Keytruda (pembrolizumab).

NeoImmune’s Hyleukin-7 (NT-I7) will enter a trial alongside the Merck anti-PD1 therapy in relapsed/refractory (R/R) advanced solid tumors.

The goal of the Phase Ib/IIa study is to establish a recommended dosing regimen and explore the preliminary anti-tumor activity of the combination in patients with both checkpoint inhibitor (CPI)-treated and CPI-naïve R/R tumors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology